0001140361-21-028220.txt : 20210813 0001140361-21-028220.hdr.sgml : 20210813 20210813122544 ACCESSION NUMBER: 0001140361-21-028220 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20210811 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210813 DATE AS OF CHANGE: 20210813 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SC Health Corp CENTRAL INDEX KEY: 0001764301 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 000000000 STATE OF INCORPORATION: E9 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38972 FILM NUMBER: 211170894 BUSINESS ADDRESS: STREET 1: 108 ROBINSON ROAD #10-00 CITY: SINGAPORE STATE: U0 ZIP: 068900 BUSINESS PHONE: 65 6438 1080 MAIL ADDRESS: STREET 1: 108 ROBINSON ROAD #10-00 CITY: SINGAPORE STATE: U0 ZIP: 068900 8-K 1 brhc10028000_8k.htm 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): August 11, 2021

SC Health Corporation
(Exact name of registrant as specified in its charter)

Cayman Islands
001-38972
 N/A
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)

108 Robinson Road #10-00
Singapore
  
068900
(Address of principal executive offices)
  
(Zip Code)

+65 6438-1080
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 ☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 
Title of each class
  
Trading Symbol(s)
  
Name of each exchange on which registered
 
Units, each consisting of one Class A ordinary share, $0.0001 par value, and one half of one warrant
   SCPE.U
  
New York Stock Exchange LLC
 
Class A ordinary shares, par value $0.0001 per share
   SCPE  
New York Stock Exchange LLC
 
Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share
   SCPE WS
  
New York Stock Exchange LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01.
Regulation FD Disclosure.

On August 11, 2021, SC Health Corporation, a Cayman Islands exempted company (the “Company”), and Rockley Photonics Holdings Limited, a Cayman Islands exempted company, jointly issued a press release announcing that they have closed their previously announced business combination. A copy of the press release is attached as Exhibit 99.1 hereto and incorporated by reference herein.

The information in this Item 7.01 and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liabilities under that section, and shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act of 1933, as amended (the “Securities Act”) or the Exchange Act, regardless of any general incorporation language in such filings.

Item 9.01.
Financial Statements and Exhibits.

(d) Exhibits

Exhibit
No.
  
Description
 
Press Release, dated August 11, 2021.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
SC Health Corporation
   
Date: August 13, 2021
By:
/s/ Angelo John Coloma
 
Name:
Angelo John Coloma
 
Title:
Chief Executive Officer


EX-99.1 2 brhc10028000_ex99-1.htm EXHIBIT 99.1
Exhibit 99.1



Rockley Photonics Announces Successful Closing of Business Combination with SC Health Corp.

Rockley receives approximately $168 million in gross proceeds; combined company to begin trading under ticker “RKLY” on August 12

Oxford, UK, and Pasadena, Calif. – August 11, 2021 – Rockley Photonics, Ltd. (“the Company” or “Rockley”), a leading global silicon photonics technology company, today announced the completion of its business combination with SC Health Corp. (“SC Health”). The combined company will retain the Rockley Photonics, Ltd. name as a subsidiary of Rockley Photonics Holdings, Ltd., which will commence trading on the NYSE under the new ticker symbol “RKLY” on August 12. The transaction was approved by SC Health's shareholders on August 6, following which the High Court of Justice of England and Wales approved the Scheme of Arrangement on August 9.

The approximately $167.8 million in gross proceeds available to Rockley following the combination is expected to enable the Company to accelerate the commercial launch of its unique sensing platform and execute the 2023 and 2024 revenue projections as outlined in prior investor presentations. The platform is positioned to revolutionize consumer health and wellness by enabling continuous, non-invasive monitoring of multiple biomarkers, including core body temperature, blood pressure, body hydration, alcohol, lactate, and glucose, among others. Rockley is working closely and deeply with some of the world’s largest manufacturers of consumer electronics and wearables to provide them with a “clinic-on-the-wrist” digital health sensor system. Rockley’s end-to-end sensing platform will combine hardware and application firmware in a module for OEM manufacturers that can be augmented with cloud analytics for certain clinical/medical partnership applications, enabling these customers to provide meaningful and actionable insights to their users.

“Silicon photonics has tremendous potential to transform multiple industries through a broad range of applications, particularly in the health and wellness space by bringing laboratory-grade measurement on the wrist much closer to reality,” said Dr. Andrew Rickman, chief executive officer and founder of Rockley Photonics. “As we continue on the next phase of our growth as a public company, we are in a much stronger position to create solutions that can provide a new class of actionable insights, transform digital healthcare, and deliver life-changing benefits to people across the globe.”

A.J. Coloma, chief executive officer of SC Health, added, “Rockley’s technology is truly revolutionary. By giving access to personalized insights and information, Rockley’s unique sensing platform lets people self-manage their well-being. Easy, everyday access to this data has the power to transform the healthcare paradigm, moving away from costly chronic care and focusing on prevention and early intervention, thereby keeping people at the peak of health. Rockley is now well poised to further solidify their leadership position in the industry, and we are excited about the abundance of growth opportunities ahead, not only in the consumer health space, but also in medtech and beyond. We look forward to continuing to work alongside Andrew and his team to fully realize the myriad applications of the company’s technology.”

Board of Directors

With the completion of this business combination, Rockley also announced the appointment of a diverse board of directors. The new board will comprise of seven directors, including three women and one self-identified minority director, who bring extensive public company board experience and deep expertise in each of their respective fields:

 •
Dr. Andrew Rickman, Ph.D., OBE1, Rockley CEO and founder, will serve as chairman of the board.

Page 1 of 4



 •
William Huyett is director emeritus of McKinsey and Company, where he spent 30 years serving global clients in biopharmaceuticals, medical devices, industrial, and other technology-intensive companies. Mr. Huyett will serve as senior independent director.

•
Dr. Caroline Brown, Ph.D., has 20 years of board experience, has been an independent director on Rockley’s board since January 2019, and sits on the boards of IP Group plc, Georgia Capital plc and Luceco plc. Dr. Brown has been appointed as chair of audit committee.

•
Brian J. Blaser has over 25 years of experience in the medical devices industry and retired from Abbott Laboratories in 2019 as executive vice president of diagnostic products after holding a number of senior and corporate roles in operations and strategy.

•
Karim Karti, a healthcare industry veteran, is the chair of MedTech Acquisition, was previously the chief operating officer of iRhythm Technologies, and served in roles of increasing seniority over 22 years at General Electric.

•
Michele Klein has 20 years of semiconductor industry experience and serves on the boards of Aviat Networks and Intevac. Earlier she was a director of Photon Control, an investor for Applied Ventures, the VC arm of Applied Materials, and CEO of diagnostic equipment companies.

•
Dr. Pamela Puryear, Ph.D., an expert on human capital, is the executive vice president of global human resources at Walgreen Boots and was previously a senior vice president and chief human resources at Zimmer Biomet and the senior vice president and chief talent officer at Pfizer.
 
1 Order of the British Empire
 
Transaction Details

As a result of the business combination, Rockley has received approximately $167.8 million in gross proceeds. This includes $17.8 million from SC Health, as well as $150 million from the financing completed in connection with the announcement of the business combination, led by top-tier institutional investors including Senvest Management LLC and UBS O’Connor and participation from Medtronic.

Advisors

Cowen and Company LLC served as exclusive financial advisor to Rockley and Pillsbury Winthrop Shaw Pittman LLP served as legal counsel. BofA Securities served as exclusive financial advisor to SC Health and Ropes & Gray LLP served as legal counsel. BofA Securities and Cowen and Company LLC served as placement agents on the PIPE.

About Rockley Photonics

A global leader in silicon photonics, Rockley is developing a comprehensive range of photonic integrated circuits and associated modules, sensors, and full-stack solutions. From next-generation sensing platforms specifically designed for mobile health monitoring and machine vision to high-speed, high-volume solutions for data communications, Rockley is laying the foundation for a new generation of applications across multiple industries. Rockley believes that photonics will eventually become as pervasive as micro-electronics, and it has developed a platform with the power and flexibility needed to address both mass markets and a wide variety of vertical applications.

Formed in 2013 by Dr. Andrew Rickman (who previously founded the first commercial silicon photonics company, Bookham Technology), Rockley is uniquely positioned to support hyper-scale manufacturing and address a multitude of high-volume markets. Rockley has partnered with numerous Tier-1 customers across a diverse range of industries to deliver the complex optical systems required to bring transformational products to market.

Page 2 of 4


To learn more about Rockley, visit rockleyphotonics.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements in this press release that are not historical facts constitute “forward-looking statements” for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding Rockley’s future expectations, beliefs, plans, objectives, and assumptions regarding future events or performance. The words “anticipate,” “believe,” “continue,” “could,” “enable,” “estimate,” “eventual,” “expect,” “future,” “intend,” “may,” “might,” “opportunity,” “outlook,” “plan,” “possible,” “position,” “potential,” “predict,” “project,” “revolutionize,” “seem,” “should,” “trend,” “will,” “would” and other terms that predict or indicate future events, trends, or expectations, and similar expressions or the negative of such expressions may identify forward-looking statements, but the absence of these words or terms does not mean that a statement is not forward-looking. Forward-looking statements in this press release include, but are not limited to, statements regarding the following: (a) the gross proceeds available to the Company after the business combination, the Company’s anticipated use of proceeds and capital available after the business combination, and that such proceeds are expected to enable the Company to accelerate the commercial launch of its sensing platform; (b) the anticipated features and benefits of the Company’s platform, products, and technology; (c) the Company’s platform being positioned to revolutionize consumer health and wellness by enabling continuous, non-invasive monitoring of multiple biomarkers, including core body temperature, blood pressure, body hydration, alcohol, lactate, and glucose, among others; (d) the Company’s collaboration with manufacturers of consumer electronics and wearables to provide them with a “clinic-on-the-wrist” digital health sensor system; (e) the Company’s sensing platform, which will combine hardware and application firmware in a module that can be augmented with cloud analytics, and the anticipated benefits thereof; (f) the ability of the capital from the business combination to advance the development of commercial opportunities for the application of silicon photonics across industries; (g) the potential of silicon photonics to transform multiple industries through a range of applications; (h) the Company’s ability to create solutions that can provide a new class of actionable insights, transform digital healthcare, and deliver life-changing benefits; (i) the belief as to the revolutionary nature of Rockley’s technology; and (j) growth opportunities and Rockley’s leadership position in the industry.

Forward-looking statements are subject to several risks and uncertainties (many of which are beyond the Company’s control) or other assumptions that may cause actual results or performance to differ materially from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the following: (i) the Company’s ability to achieve commercial production of its products and technology, including in a timely and cost-effective manner; (ii) the Company’s ability to achieve customer design wins, convert memoranda of understanding and development contracts into production contracts, and achieve customer acceptance of its products and technology; (iii) risks related to purchase orders, including the lack of long-term purchase commitments, the cancellation, reduction, delay, or other changes in customer purchase orders, and if and to the extent customers seek to enter into licensing arrangements in lieu of purchases; (iv) the Company’s history of losses and need for additional capital and its ability to access additional financing to support its operations and execute on its business plan, as well as the risks associated with any future financings; (v) legal and regulatory risks, including those related to its products and technology and any threatened or actual litigation; (vi) risks associated with its fabless manufacturing model and dependency on third-party suppliers; (vii) the Company’s reliance on a few significant customers for a majority of its revenue and its ability to expand and diversify its customer base; (viii) the Company’s financial performance; (ix) the impacts of COVID-19 on the Company, its customers and suppliers, its target markets, and the economy; (x) the Company’s ability to successfully manage growth and its operations as a public company; (xi) fluctuations in the Company’s stock price and the Company’s ability to maintain the listing of its ordinary shares on the NYSE; (xii) the Company’s ability to anticipate and respond to industry trends and customer requirements; (xiii) changes in the Company’s current and future target markets; (xiv) intellectual property risks; (xv) the Company’s ability to compete successfully; (xvi) market opportunity and market demand for, and acceptance of, the Company’s products and technology, as well as the customer products into which the Company’s products and technology are incorporated; (xvii) risks related to international operations; (xviii) risks related to cybersecurity, privacy, and infrastructure; (xix) risks related to financial and accounting matters; (xx) general economic, financial, legal, political, and business conditions and changes in domestic and foreign markets; (xxi) the Company’s ability to realize the anticipated benefits of the business combination; and (xxii) changes adversely affecting the businesses or markets in which the Company is engaged, as well as other factors described under the heading “Risk Factors” in the prospectus/proxy statement filed by the Company on July 22, 2021 and in other documents the Company files with the Securities and Exchange Commission in the future. The forward-looking statements contained in this press release are based on various assumptions, whether or not identified in this press release, and on the Company’s current expectations, beliefs, and assumptions and are not predictions of actual performance. If any of these risks or uncertainties materialize, or should any of these assumptions prove incorrect, actual results may differ materially from those discussed in or implied by these forward-looking statements. There can be no assurance that future developments affecting the Company will be those that have been anticipated. These forward-looking statements speak only as of the date hereof and the Company specifically disclaims any obligation to update or revise any forward-looking statements, whether because of new information, future events, or otherwise.

Page 3 of 4


Contact Information

For Rockley
Media
John Christiansen, Camilla Scassellati Sforzolini
Sard Verbinnen & Co
Rockley-SVC@sardverb.com

Investors
Gwyn Lauber
Vice President of Investor Relations
Rockley Photonics
investors@rockleyphotonics.com

# # #


Page 4 of 4
 EX-101.SCH 3 scpe-20210811.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 scpe-20210811_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 scpe-20210811_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Class of Stock [Domain] Common Class A [Member] Class of Stock [Axis] Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Ex Transition Period Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Entity Listings [Table] Entity Listings [Line Items] Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Units, each consisting of one Class A ordinary share, $0.0001 par value, and one half of one warrant [Member] Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share [Member] EX-101.PRE 6 scpe-20210811_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 image01.jpg begin 644 image01.jpg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end XML 8 brhc10028000_8k_htm.xml IDEA: XBRL DOCUMENT 0001764301 2021-08-11 2021-08-11 0001764301 scpe:WarrantsEachWholeWarrantExercisableForOneClassAOrdinaryShareAtAnExercisePriceOf1150PerShareMember 2021-08-11 2021-08-11 0001764301 scpe:UnitsEachConsistingOfOneClassAOrdinaryShare00001ParValueAndOneHalfOfOneWarrantMember 2021-08-11 2021-08-11 0001764301 us-gaap:CommonClassAMember 2021-08-11 2021-08-11 false SC Health Corp SC Health Corp 00-0000000 0001764301 8-K 2021-08-11 E9 001-38972 108 Robinson Road #10-00 SG 068900 65 6 438-1080 false false false false Units, each consisting of one Class A ordinary share, $0.0001 par value, and one half of one warrant SCPE.U NYSE Class A ordinary shares, par value $0.0001 per share SCPE NYSE Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share SCPE WS NYSE true false XML 9 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information
Aug. 11, 2021
Entity Listings [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 11, 2021
Entity Registrant Name SC Health Corp
Entity Incorporation, State or Country Code E9
Entity File Number 001-38972
Entity Tax Identification Number 00-0000000
Entity Address, Address Line One 108 Robinson Road #10-00
Entity Address, Country SG
Entity Address, Postal Zip Code 068900
City Area Code 65 6
Local Phone Number 438-1080
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity Central Index Key 0001764301
Units, each consisting of one Class A ordinary share, $0.0001 par value, and one half of one warrant [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security Units, each consisting of one Class A ordinary share, $0.0001 par value, and one half of one warrant
Trading Symbol SCPE.U
Security Exchange Name NYSE
Common Class A [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security Class A ordinary shares, par value $0.0001 per share
Trading Symbol SCPE
Security Exchange Name NYSE
Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share
Trading Symbol SCPE WS
Security Exchange Name NYSE
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 4 96 1 false 3 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://schealthcorp.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports brhc10028000_8k.htm brhc10028000_ex99-1.htm scpe-20210811.xsd scpe-20210811_def.xml scpe-20210811_lab.xml scpe-20210811_pre.xml http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "brhc10028000_8k.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 4, "dts": { "definitionLink": { "local": [ "scpe-20210811_def.xml" ] }, "inline": { "local": [ "brhc10028000_8k.htm" ] }, "labelLink": { "local": [ "scpe-20210811_lab.xml" ] }, "presentationLink": { "local": [ "scpe-20210811_pre.xml" ] }, "schema": { "local": [ "scpe-20210811.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd" ] } }, "elementCount": 37, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 5, "total": 5 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 2, "memberStandard": 1, "nsprefix": "scpe", "nsuri": "http://schealthcorp.com/20210811", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "brhc10028000_8k.htm", "contextRef": "c20210811to20210811", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "role": "http://schealthcorp.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "brhc10028000_8k.htm", "contextRef": "c20210811to20210811", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 3, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://schealthcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://schealthcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://schealthcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://schealthcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://schealthcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://schealthcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://schealthcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://schealthcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://schealthcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://schealthcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://schealthcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://schealthcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://schealthcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://schealthcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://schealthcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://schealthcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://schealthcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://schealthcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityListingsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Listings [Line Items]" } } }, "localname": "EntityListingsLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://schealthcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityListingsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container for exchange listing information for an entity", "label": "Entity Listings [Table]" } } }, "localname": "EntityListingsTable", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://schealthcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://schealthcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://schealthcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://schealthcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://schealthcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://schealthcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://schealthcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://schealthcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://schealthcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://schealthcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://schealthcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://schealthcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "scpe_UnitsEachConsistingOfOneClassAOrdinaryShare00001ParValueAndOneHalfOfOneWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Units, each consisting of one Class A ordinary share, $0.0001 par value, and one half of one warrant [Member]" } } }, "localname": "UnitsEachConsistingOfOneClassAOrdinaryShare00001ParValueAndOneHalfOfOneWarrantMember", "nsuri": "http://schealthcorp.com/20210811", "presentation": [ "http://schealthcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "scpe_WarrantsEachWholeWarrantExercisableForOneClassAOrdinaryShareAtAnExercisePriceOf1150PerShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share [Member]" } } }, "localname": "WarrantsEachWholeWarrantExercisableForOneClassAOrdinaryShareAtAnExercisePriceOf1150PerShareMember", "nsuri": "http://schealthcorp.com/20210811", "presentation": [ "http://schealthcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://schealthcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Class A [Member]" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://schealthcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://schealthcorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 17 0001140361-21-028220-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-21-028220-xbrl.zip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end